Zhang Dongfeng, Song Xiantao, Raposeiras-Roubín Sergio, Abu-Assi Emad, Simao Henriques Jose Paulo, D'Ascenzo Fabrizio, Saucedo Jorge, González-Juanatey José Ramón, Wilton Stephen B, Kikkert Wouter J, Nuñez-Gil Iván, Ariza-Sole Albert, Alexopoulos Dimitrios, Liebetrau Christoph, Kawaji Tetsuma, Moretti Claudio, Huczek Zenon, Nie Shaoping, Fujii Toshiharu, Correia Luis, Kawashiri Masa-Aki, Southern Danielle, Kalpak Oliver
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chaoyang District, Beijing 100029, China.
Ther Adv Chronic Dis. 2021 Sep 29;12:20406223211046999. doi: 10.1177/20406223211046999. eCollection 2021.
Treatment of acute myocardial infarction (AMI) patients with prior stroke is a common clinical dilemma. Currently, the application of optimal medical therapy (OMT) and its impact on clinical outcomes are not clear in this patient population.
We retrieved 765 AMI patients with prior stroke who underwent percutaneous coronary intervention (PCI) during the index hospitalization from the international multicenter BleeMACS registry. All of the subjects were divided into two groups based on the prescription they were given prior to discharge. Baseline characteristics and procedural variables were compared between the OMT and non-OMT groups. Mortality, re-AMI, major adverse cardiovascular events (MACE), and bleeding were followed-up for 1 year.
Approximately 5% of all patients presenting with AMI were admitted to the hospital for ischemic stroke. Although the prescription rate of each OMT medication was reasonably high (73.3%-97.3%), 47.7% lacked at least one OMT medication. Patients receiving OMT showed a significantly decreased occurrence of mortality (4.5% vs 15.1%, < 0.001), re-AMI (4.2% vs 9.3%, = 0.004), and the composite endpoint of death/re-AMI (8.6% vs 20.5%, < 0.001) compared to those without OMT. No significant difference was observed between the groups regarding bleeding. After adjusting for confounding factors, OMT was the independent protective factor of 1-year mortality, while age was the independent risk factors.
OMT at discharge was associated with a significantly lower 1-year mortality of patients with AMI and prior stroke in clinical practice. However, OMT was provided to just half of the eligible patients, leaving room for substantial improvement.
NCT02466854.
治疗合并既往卒中的急性心肌梗死(AMI)患者是常见的临床难题。目前,最佳药物治疗(OMT)在该患者群体中的应用情况及其对临床结局的影响尚不清楚。
我们从国际多中心BleeMACS注册研究中检索了765例在本次住院期间接受经皮冠状动脉介入治疗(PCI)的合并既往卒中的AMI患者。所有受试者根据出院前的用药情况分为两组。比较OMT组和非OMT组的基线特征和手术变量。对死亡率、再发AMI、主要不良心血管事件(MACE)和出血情况进行了1年的随访。
所有AMI患者中约5%因缺血性卒中入院。尽管每种OMT药物的处方率相当高(73.3%-97.3%),但47.7%的患者至少缺少一种OMT药物。与未接受OMT的患者相比,接受OMT的患者死亡率(4.5%对15.1%,<0.001)、再发AMI(4.2%对9.3%,=0.004)以及死亡/再发AMI复合终点(8.6%对20.5%,<0.001)的发生率显著降低。两组在出血方面未观察到显著差异。调整混杂因素后,OMT是1年死亡率的独立保护因素,而年龄是独立危险因素。
在临床实践中,出院时进行OMT与合并既往卒中的AMI患者1年死亡率显著降低相关。然而,只有一半的符合条件患者接受了OMT,仍有很大的改进空间。
NCT02466854。